ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024 · Cancer Research · 24 citations
https://doi.org/10.1158/0008-5472.can-23-0438
B
Bomiao Hu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
83
Papers
549
Citations
3
h-index
3
i10-index
Bomiao Hu is an academic researcher. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & RNA modifications and cancer & Cytokine Signaling Pathways and Interactions. The author has an h-index of 3, co-authored 71 publications.
ORCID: 0009-0001-4697-0577Papers by this author
worksFigure S4 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024 · 0 citations
https://doi.org/10.1158/0008-5472.25607394
Table S2 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024 · 0 citations
https://doi.org/10.1158/0008-5472.25607376
Figure S6 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024 · 0 citations
https://doi.org/10.1158/0008-5472.25607388.v1
Figure S5 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024 · 0 citations
https://doi.org/10.1158/0008-5472.25607391
Figure S6 from ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
2024 · 0 citations
https://doi.org/10.1158/0008-5472.25607388
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat